Summary:
A Randomized, Double-Blind, Multicenter, 3-Stage, Efficacy and Safety Study of NI-071 and US-Licensed Remicade® (Infliximab) for the Treatment of Patients with Rheumatoid Arthritis
Qualified Participants Must:
• Be between 18 and 75 years of age at screening
• Must be taking a stable dose of Methotrexate for at least 3 months
• Women of childbearing potential and all males must use at least 1 acceptable form of birth control throughout the study and for 16 weeks after the last dose.
Qualified Participants May Receive:
Compensation for time and travel